Source - LSE Regulatory
RNS Number : 6765S
Diurnal Group PLC
15 July 2022
 

15 July 2022

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealings

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the issue and allotment of 321,292 ordinary shares of £0.05 pursuant to vesting of the deferred bonus share awards granted under the Diurnal Group plc Long Term Incentive Plan details of which were announced on 2 August 2021, including 163,792 ordinary shares to persons discharging managerial responsibilities ("PDMR").

 

PDMR                            Total number of New                    Nature of issuance

                                      Ordinary Shares issued                     

Richard Bungay              84,000                                          Vesting of deferred bonus award

Richard Ross                  26,892                                          Vesting of deferred bonus award

John Porter                     30,500                                          Vesting of deferred bonus award

Stewart Jones                 22,400                                          Vesting of deferred bonus award

 

The shares were issued under the Company's Employee Benefit Trust scheme.

 

Following the issue of shares, the total beneficial interest of Richard Bungay is 337,578 Ordinary Shares, representing 0.20% of the total voting rights, the total beneficial interest of Richard Ross and his connected parties is 2,284,047 Ordinary Shares, representing 1.34% of the total voting rights, the total beneficial interest of John Porter is 143,245 Ordinary Shares, representing 0.08% of the total voting rights, and the total beneficial interest of Stewart Jones is 130,282 Ordinary Shares, representing 0.08% of the total voting rights.

 

The new ordinary shares are being issued pursuant to the Company's block admission facility, details of which were announced on 13 December 2021. The new ordinary shares will rank pari passu with the existing shares of common stock of the Company. Following the issue of shares, the Company's issued ordinary share capital will consist of 170,040,825 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in Diurnal following Admission will be 170,040,825.

 

The above figure of 170,040,825 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Interim Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Acquisition of ordinary shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




Nil

84,000

 

 






d)

 

Aggregated information




- Aggregated volume

As above



- Price

 



e)

 

Date of the transaction

 

15 July 2022

f)

 

Place of the transaction

 

XLON

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Richard Ross

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Scientific Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Acquisition of ordinary shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




Nil

26,892

 

 






d)

 

Aggregated information




- Aggregated volume

As above



- Price

 



e)

 

Date of the transaction

 

 15 July 2022

f)

 

Place of the transaction

 

XLON

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

John Porter

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Medical Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Acquisition of ordinary shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




Nil

30,500

 

 






d)

 

Aggregated information




- Aggregated volume

As above



- Price

 



e)

 

Date of the transaction

 

15 July 2022

f)

 

Place of the transaction

 

XLON

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Stewart Jones

2

 

Reason for the notification

 

a)

 

Position/status

 

Operations Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Acquisition of ordinary shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




Nil

22,400

 

 






d)

 

Aggregated information




- Aggregated volume

As above



- Price

 



e)

 

Date of the transaction

 

15 July 2022

f)

 

Place of the transaction

 

XLON

 

 

 

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Richard Bungay, Interim Chief Executive Officer

 


 

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

 

Corporate Broking: Rupert Dearden

 


 

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

+44 (0) 20 7710 7600

Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown

 

Corporate Broking: Nick Adams, Nick Harland

 


 

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


Alex Davis


 

Notes to Editors

 

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFILDFIELIF
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts